Interim commissioning guidance for tirzepatide implementation published

The NHS has released interim commissioning guidance to support the implementation of the NICE Technology Appraisal (NICE TA1026) and the NICE Funding Variation for tirzepatide (Mounjaro®) in the management of obesity.

This framework aims to facilitate the phased rollout of tirzepatide within NHS specialist weight management services and primary care settings over the next three years.

The guidance provides clarity on the eligible patient cohorts, outlining those who will benefit from treatment in accordance with NICE recommendations. A prioritisation strategy has been established to ensure that those most in need gain timely access to this medication.

The phased implementation approach will help integrate tirzepatide into existing weight management pathways while maintaining a structured and equitable distribution process.

Funding allocations have been designated to Integrated Care Boards (ICBs) to ensure the effective and consistent delivery of tirzepatide across NHS systems.

These allocations align with the NICE Funding Variation framework to promote fair access and sustainable implementation across regions.

Tirzepatide represents a significant advancement in obesity management, providing an additional treatment option for eligible patients struggling with weight-related health concerns. The commissioning guidance underscores the importance of structured rollout and equitable access, ensuring that the medication is introduced effectively into the NHS system.

This interim guidance serves as a critical resource for commissioners, healthcare providers, and policymakers as they work to integrate tirzepatide into obesity management services. Further updates and refinements are expected as the implementation progresses over the coming years.